- Home
- SPHR vs HCM Comparison
SPHR vs HCM Comparison
Compare SPHR & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPHR | HCM |
|---|---|---|
| Founded | 2020 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.7B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | SPHR | HCM |
|---|---|---|
| Price | $114.24 | $15.29 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 12 | 1 |
| Target Price | ★ $96.36 | $13.75 |
| AVG Volume (30 Days) | ★ 700.2K | 23.8K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.03 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $1,220,045,000.00 | N/A |
| Revenue This Year | $12.86 | N/A |
| Revenue Next Year | N/A | $16.12 |
| P/E Ratio | $154.38 | ★ $5.49 |
| Revenue Growth | ★ 18.81 | N/A |
| 52 Week Low | $23.89 | $11.51 |
| 52 Week High | $118.14 | $19.50 |
Technical Indicators
Market Signals| Indicator | SPHR | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 70.03 | 47.32 |
| Support Level | $113.97 | $14.68 |
| Resistance Level | $118.14 | $15.33 |
| Average True Range (ATR) | 4.83 | 0.39 |
| MACD | 1.96 | -0.04 |
| Stochastic Oscillator | 87.69 | 46.15 |
Price Performance
Historical ComparisonAbout SPHR Sphere Entertainment Co.
Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments which includeSphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.